Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
259.20B
Market cap259.20B
Price-Earnings ratio
17.66
Price-Earnings ratio17.66
Dividend yield
2.67%
Dividend yield2.67%
Average volume
1.20M
Average volume1.20M
High today
$122.99
High today$122.99
Low today
$122.26
Low today$122.26
Open price
$122.29
Open price$122.29
Volume
1.20M
Volume1.20M
52 Week high
$130.46
52 Week high$130.46
52 Week low
$96.06
52 Week low$96.06

NVS News

Benzinga 2d
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per da...

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Seeking Alpha 2d
Monte Rosa stock rises after pact with Novartis

Shares of Monte Rosa Therapeutics (NASDAQ: NASDAQ:GLUE) rose after it announced a new collaboration with Novartis (NYSE:NVS) to advance the development of molec...

Monte Rosa stock rises after pact with Novartis
TipRanks 2d
Monte Rosa’s Stock Skyrockets on $5.7B Deal with Norvatis

Swiss giant drug producer Novartis (NVS) has found a new destination for its recent partnership spree. On Monday, Monte Rosa Therapeutics (GLUE), a Massachusett...

Analyst ratings

60%

of 25 ratings
Buy
20%
Hold
60%
Sell
20%

More NVS News

TipRanks 2d
Monte Rosa Therapeutics announces collaboration with Novartis

Monte Rosa Therapeutics (GLUE) announced an agreement to collaborate with Novartis (NVS) to develop novel degraders for immune-mediated diseases. The agreement...

Seeking Alpha 5d
Novartis cut to Sell at Goldman Sachs on near-term risks

Novartis (NYSE:NVS) has been downgraded to Sell from Neutral at Goldman Sachs, citing concerns that recent share price outperformance and multiple expansion do...

Novartis cut to Sell at Goldman Sachs on near-term risks
TipRanks 6d
Novartis downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs analyst James Quigley downgraded Novartis (NVS) to Sell from Neutral with a price target of $118, down from $119. Novartis has been the best perfo...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.